Nursing care
Thrombolytics: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 5 min read · Updated September 2026
Short answer
Thrombolytics such as alteplase and tenecteplase dissolve an existing clot and are given within a strict time window, most often 3 to 4.5 hours for ischemic stroke or up to 12 hours for STEMI. Any recent major bleed, recent surgery, or history of intracranial hemorrhage rules the drug out entirely, so the nursing job starts with a screening checklist, not the infusion.
Why this drug and not another
Thrombolytics, or fibrinolytics, break down an existing clot by converting plasminogen to plasmin, which then degrades fibrin. This makes them fundamentally different from anticoagulants, which prevent new clot formation but do nothing to an existing one. Alteplase, tenecteplase, and reteplase are the agents used most often for acute ischemic stroke, STEMI, and massive pulmonary embolism.
The decision to use a thrombolytic instead of a mechanical intervention, such as percutaneous coronary intervention for STEMI or thrombectomy for stroke, depends on time from symptom onset and access to that intervention. A rural facility without a cath lab may thrombolyse a STEMI patient and transfer, while a stroke center within reach of endovascular therapy may favor thrombectomy for a large-vessel occlusion instead. The nurse needs to know why this particular patient is getting a clot-dissolving drug rather than a clot-removing procedure, because the two pathways carry different monitoring priorities afterward.
Administration and timing
Time is the variable that decides everything. For ischemic stroke, alteplase is given within 3 hours of symptom onset for most patients, extended to 4.5 hours for a narrower eligible group; tenecteplase is increasingly used as an alternative with a simpler bolus dosing regimen. For STEMI, the window extends out to 12 hours from symptom onset, though benefit is greatest within the first few hours.
Two large-bore IV lines are established before the infusion starts, one for the thrombolytic and one kept free for any emergency medication. Blood is drawn for baseline coagulation studies, platelet count, and type and screen before the first dose, not after. No IM injections, no arterial punctures, and no unnecessary venipunctures once the drug is running, since every needle stick becomes a bleeding site. Dosing is weight-based and calculated carefully, since an overdose sharply raises hemorrhage risk without added benefit.
Monitoring parameters
Neurological checks and vital signs are done on a fixed, frequent schedule during and after a stroke thrombolytic infusion, typically every 15 minutes for the first two hours, then tapering as the risk window passes. A new headache, a sudden change in level of consciousness, or a new neurological deficit during the infusion is treated as a possible intracranial hemorrhage until proven otherwise, and the infusion is stopped immediately.
For STEMI patients, continuous cardiac monitoring tracks for reperfusion arrhythmias, which are actually a sign the clot is dissolving and blood flow is returning, and for resolution of ST-segment changes. Blood pressure is controlled tightly before and during the infusion, since hypertension raises the risk of hemorrhagic conversion; a systolic pressure above roughly 180 mmHg is a threshold many stroke protocols require to be corrected before treatment can proceed. Access sites, gums, and urine are checked for oozing throughout, not just at the end of the infusion.
Adverse effects to report
Intracranial hemorrhage is the adverse effect that defines this drug class and the one every other assessment exists to catch early. A sudden severe headache, new vomiting, a drop in consciousness, or a new focal deficit during or shortly after infusion is reported immediately and the infusion is stopped without waiting for imaging confirmation.
Other bleeding to report includes gum bleeding that will not stop, blood in urine or stool, oozing at IV sites that does not resolve with pressure, and any sign of retroperitoneal bleeding such as flank or back pain with a falling blood pressure. Reperfusion arrhythmias after a STEMI thrombolytic are expected and usually self-limited, but sustained ventricular tachycardia or hemodynamic instability still needs immediate reporting and treatment. Angioedema involving the lips or tongue, more common with alteplase in patients on ACE inhibitors, is a less frequent but airway-threatening reaction to watch for.
Contraindications and cautions
The contraindication list for thrombolytics is long, and any recent bleed or recent surgery ends the conversation before the drug is drawn up. Absolute contraindications include active internal bleeding, any history of intracranial hemorrhage, known bleeding disorder, recent intracranial or intraspinal surgery, and severe uncontrolled hypertension. Suspected aortic dissection is an absolute contraindication in the STEMI setting specifically.
Relative contraindications require the prescriber to weigh benefit against risk: major surgery or serious trauma within the past two to three weeks, gastrointestinal bleeding within the past three weeks, pregnancy, and recent noncompressible vascular puncture. The nurse's role is completing the screening checklist thoroughly and asking the questions that surface a bleed or a procedure the patient did not think to mention, since a missed contraindication here is not a minor error.
Teaching points the exam tests
Exam questions on thrombolytics usually center on recognizing a contraindication buried in a patient history, so read every history stem for a recent fall, a recent surgery, or a bleeding disorder before answering what the nurse should do next. A question describing a patient who had abdominal surgery ten days ago is testing whether the test-taker will still pick 'administer the thrombolytic' when the answer is to hold it and notify the provider.
The second pattern tested is time-to-treatment: know that stroke thrombolytic windows are measured in hours from last known well, not from arrival, and that a delay in recognizing symptoms can make an otherwise eligible patient ineligible by the time they reach the hospital. The third pattern is post-infusion assessment priority: a new headache or neuro change after alteplase is always the answer that outranks routine vital sign documentation, because it signals the one complication this drug class is built around.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pharmacology practice questions are the closest set to what this page covers.
One question from the pharmacology set
A client with heart failure is started on furosemide 40 mg PO daily. Which findings should the nurse report to the provider before administering the next dose? Select all that apply.
Rationale
Furosemide is a loop diuretic, so the two things you are watching are potassium and kidney function. A potassium of 2.9 mEq/L is below the 3.5–5.0 reference range and puts the client at risk for dysrhythmia — hold and report. Muscle cramps with palpitations are the clinical face of that same hypokalemia, so they are reported together, not separately. A creatinine that doubles signals the diuresis has outrun renal perfusion. A blood pressure of 132/78 and a 1 kg loss are the expected response to the drug working, not reasons to hold it.
Answer: A, D, E
Common questions
What is the time window for giving alteplase in stroke?
Up to 3 hours from last known well for most patients, extended to 4.5 hours for a narrower eligible group. Time from symptom onset, not time of arrival, is what defines the window.
Why would recent surgery rule out a thrombolytic?
Recent major surgery leaves a fresh site that cannot form a stable clot while the drug is dissolving fibrin systemically, creating a high risk of uncontrolled bleeding at that site. Most protocols treat surgery within two to three weeks as a contraindication requiring prescriber judgment or outright exclusion.
What is the priority assessment after giving a thrombolytic for stroke?
Frequent neurological checks and vital signs, watching specifically for a new headache, vomiting, or a change in level of consciousness, which signal possible intracranial hemorrhage. This assessment takes priority over routine documentation tasks.
Are reperfusion arrhythmias after a STEMI thrombolytic dangerous?
They are usually expected and self-limited, and often indicate the clot is dissolving and blood flow is returning. Sustained ventricular tachycardia or hemodynamic instability still needs immediate reporting and treatment.
Can a thrombolytic and an anticoagulant be given together?
Combining them sharply raises bleeding risk and is managed cautiously with strict protocols on timing and dose. This decision belongs to the prescriber and depends on the specific clinical indication.
More on pharmacology
Guides on this